04 November 2025
04 November 2025
Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.
Among the medicines to be produced at the site will be orforglipron, the company鈥檚 oral small-molecule GLP-1 receptor agonist.
The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme.
The proposed biosimilar to J&J鈥檚 Simponi was rejected by the FDA due to manufacturing concerns.
Pfizer called Novo Nordisk鈥檚 last-minute bid to acquire Metsera 鈥渞eckless and unprecedented鈥�.
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
